Two Cases of Epidermal Growth Factor Receptor L861R Mutation‐Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib
Cancer Reports · 2025
DOI: 10.1002/cnr2.70420 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Kei Kagawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Afatinib, Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epidermal growth factor receptor (EGFR) mutations are detected in approximately 40%–50% of patients with lung adenocarcinoma in Asian populations and in around 10% of patients in Western populations. Among these, the EGFR L861R mutation is uncommon and undetectable using conventional polymerase chain reaction methods. Recently, clinically available next‐generation sequencing (NGS) has been used to detect L861R mutations, potentially increasing the number of identified cases of L861R‐positive non‐small cell lung cancer. Herein, we present two cases of EGFR L861R‐mutated lung adenocarcinoma treated with afatinib and osimertinib to evaluate the clinical efficacy and tolerability of these targeted therapies. Case Case 1: A 63‐year‐old man with lung adenocarcinoma harboring an EGFR L861R mutation (cStage IVB) received afatinib 40 mg/day. Computer tomography (CT) on Day 49 showed shrinkage of the primary tumor, accompanied by a decrease in tumor markers. The afatinib dose was reduced to 30 mg/day due to Grade 1 diarrhea and an acneiform rash. Ground‐glass opacities were subsequently observed around the tumor. Although pneumonitis was initially suspected, the findings were subsequently considered consistent with carcinomatous lymphangitis. Consequently, afatinib was discontinued on Day 56. Case 2: An 83‐year‐old man with lung adenocarcinoma harboring an EGFR L861R mutation (cStage IVB) received osimertinib 80 mg/day. Afatinib was avoided due to concerns regarding tolerability in the elderly. CT imaging on Day 14 showed tumor shrinkage with reduced attenuation and decreased levels of tumor markers. However, osimertinib was discontinued on Day 104 due to a Grade 3 skin rash. The response to osimertinib was evaluated as stable disease. Following treatment discontinuation, the disease progressed to multiple brain metastases, and supportive care was initiated.
Conclusion
Here, we present the first case showing the anti‐tumor efficacy of afatinib and the second case showing the anti‐tumor efficacy of osimertinib in a patient with EGFR L861R‐positive lung adenocarcinoma. Despite their short treatment durations, afatinib and osimertinib may have potential clinical activity in patients with EGFR L861R‐positive lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Respiratory Medicine, Chugoku Rosai Hospital, Kure, Japan.
- Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Physical Analysis and Therapeutic Sciences, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Kei Kagawa, Takeshi Masuda, Kiyofumi Shimoji, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada, Noboru Hattori
Zitieren
APA
Kagawa, K., Masuda, T., Shimoji, K., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Nakashima, T., Iwamoto, H., Hamada, H., & Hattori, N. (2025). Two Cases of Epidermal Growth Factor Receptor L861R Mutation‐Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib. Cancer Reports. https://doi.org/10.1002/cnr2.70420
Vancouver
Kagawa K, Masuda T, Shimoji K, Yamaguchi K, Sakamoto S, Horimasu Y, et al. Two Cases of Epidermal Growth Factor Receptor L861R Mutation‐Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib. Cancer Reports. 2025. doi:10.1002/cnr2.70420
BibTeX
@article{Kagawa2025,
author = {Kagawa, Kei and Masuda, Takeshi and Shimoji, Kiyofumi and Yamaguchi, Kakuhiro and Sakamoto, Shinjiro and Horimasu, Yasushi and Nakashima, Taku and Iwamoto, Hiroshi and Hamada, Hironobu and Hattori, Noboru},
title = {Two Cases of Epidermal Growth Factor Receptor L861R Mutation‐Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70420}
}
EUVIMED